A Phase 2 Multicenter, Double-Masked, Randomized, Placebo ControlledStudy to Investigate the Long Term Safety, Tolerability,Pharmacokinetics and Effects of ALK-001 on the Progression ofStargardt Disease
A study for patients with Stargardt disease using study drug ALK-001
Sponsor: Alkeus Pharmaceuticals, Inc
Enrolling: Male and Female Patients
IRB Number: AAAK5060
U.S. Govt. ID: NCT02402660
Contact: Edylin Bautista: 212-305-5922 / mmb2225@cum.columbia.edu
Additional Study Information: Stargardt macular degeneration isa genetic condition, which in mostcases causes vision loss early in lifeand leads to legal blindness. Thereis currently no FDA-approvedtreatment.This trial will evaluate the safetyand effects of ALK-001, a newpotential drug treatment, on theprogression of Stargardt disease.ALK-001 is a capsule administereddaily by mouth.This nationwide trial will enroll 50participants diagnosed withStargardt disease.Qualifying study participants willhave access to the experimentalmedication for 24 months, andreceive comprehensive ocular andmedical care.
This study is closed
Investigator
Stephen Tsang, MD, PhD
Do You Qualify?
Have you been diagnosed with Stargardt disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Edylin Bautista
mmb2225@cum.columbia.edu
212-305-5922
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE